FDA are all injected drugs that are used regularly to prevent migraine attacks.
But rimegepant is different because it’s an oral medication that treats migraines in progress, explained lead researcher Dr. Richard Lipton.
His team found that among nearly 1,200 migraine patients, the drug outperformed inactive placebo tablets. About 20% of patients who used one dose of rimegepant were pain-free within two hours, compared with 12% of placebo users.
Many other patients, while not pain-free, still got relief, said Lipton, who directs the Montefiore Headache Center at Albert Einstein College of Medicine in New York City.
He is also a paid consultant to rimegepant developer Biohaven Pharmaceuticals, which
